Ultragenyx Pharmaceutical COO Wladimir Hogenhuis receives $5.3M in 2018
Ultragenyx Pharmaceutical reports 2018 executive compensation
By ExecPay News
Published: April 22, 2019
Ultragenyx Pharmaceutical reported fiscal year 2018 executive compensation information on April 22, 2019.
In 2018, seven executives at Ultragenyx Pharmaceutical received on average a compensation package of $3.2M, a 7% increase compared to previous year.
Average pay of disclosed executives at Ultragenyx Pharmaceutical
Wladimir Hogenhuis, Chief Operating Officer, received $5.3M in total. 67% of Hogenhuis' compensation, or $3.5M, was in option awards. Hogenhuis also received $200K in bonus, $67K in non-equity incentive plan, $111K in salary, $1.2M in stock awards, as well as $216K in other compensation.
Camille L. Bedrosian, Chief Medical Officer, received a compensation package of $4.8M. 60% of the compensation package, or $2.9M, was in option awards.
Emil D. Kakkis, Chief Executive Officer, earned $4.8M in 2018, a 28% decrease compared to previous year.
Shalini Sharp, Chief Financial Officer, received $2.1M in 2018, which decreases by 21% compared to 2017.
Karah Parschauer, General Counsel, earned $2M in 2018, a 42% increase compared to previous year.
Thomas Kassberg, Chief Business Officer and Executive Vice President, received $1.7M in 2018, which decreases by 27% compared to 2017.
John R. Pinion II, Chief Quality Officer and Executive Vice President, Translational Sciences, earned $1.6M in 2018, a 17% decrease compared to previous year.
Related executives
Emil Kakkis
Ultragenyx Pharmaceutical
Chief Executive Officer
Shalini Sharp
Ultragenyx Pharmaceutical
Chief Financial Officer
Camille Bedrosian
Ultragenyx Pharmaceutical
Chief Medical Officer
Wladimir Hogenhuis
Ultragenyx Pharmaceutical
Chief Operating Officer
Karah Parschauer
Ultragenyx Pharmaceutical
General Counsel
John Pinion
Ultragenyx Pharmaceutical
Chief Quality Officer and Executive Vice President, Translational Sciences
Thomas Kassberg
Ultragenyx Pharmaceutical
Chief Business Officer and Executive Vice President
You may also like
Source: SEC filing on April 22, 2019.